EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes

Olivier Bourron iD, Kamel Mohammedi, Joe De Keizer, Fabrice Schneider, Samy Hadjadj iD, Pierre-Jean Saulnier

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15656 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Olivier Bourron und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université Médecine, Assistance Publique Hôpitaux de Paris (APHP), Diabetology Department, Pitié-Salpêtrière Hospital, INSERM UMRS_1138, Cen…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Peripheral Arterial Disease, Vitamin K, Amputation, Surgical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Groupement pour l'Etude des Maladies Métaboliques et Systémiques (GEMMS Poitiers, France), Société Francophone du Diabète, Association Française des Diabétiques.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The use of vitamin K antagonists (VKAs) may increase the risk of peripheral arterial disease (PAD) because vitamin K is a strong inhibitor of medial arterial calcification. Type 2 diabetes (T2D) exposes patients to an increased risk of PAD. We examined how the use of VKAs modulates the risk of incident PAD in people with T2D. Materials and Methods SURDIAGENE is a French cohort including 1468 patients with T2D with a prospective follow‐up from 2002 to 2015. The primary outcome of the current analysis was the first occurrence of PAD, a composite of lower‐limb amputation (LLA) or lower‐limb revascularization. LLA and lower‐limb revascularization were considered individually as secondary outcomes.

Results

During a 7‐year median follow‐up, PAD occurred in 147 (10%) of the 1468 participants. The use of VKAs was not significantly associated with the risk of PAD [multivariable adjusted hazard ratio (HR) 1.42, 95% confidence interval (CI), 0.88‐2.31]. During the study period, LLA and lower‐limb revascularization occurred in 82 (6%) and 105 (7%) participants, respectively. The use of VKAs was significantly associated with increased risk of LLA [multivariable adjusted HR 1.90 (95% CI, 1.04‐3.47)], but not lower‐limb revascularization [multivariable adjusted HR 1.08 (95% CI, 0.59‐1.97)].

Conclusions

In this prospective study, we did not observe any excess risk of PAD requiring lower‐limb revascularization in people with type 2 diabetes using VKAs. However, our data suggest a high risk of LLA in VKA users. Further studies are required to confirm this observation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Peripheral Arterial DiseaseVitamin KAmputation, SurgicalDiabetic AngiopathiesHumansFemaleMaleProspective StudiesAgedMiddle AgedFranceRisk FactorsFollow-Up StudiesAnticoagulantsLower ExtremityIncidence

Stichwörter der Autor:innen

cardiovascular diseasecohort studydiabetes complicationsmacrovascular diseaseobservational studytype 2 diabetes

Substanzen

Vitamin KAnticoagulants

Autor:innen und Institutionen

  • Sorbonne Université Médecine, Assistance Publique Hôpitaux de Paris (APHP), Diabetology Department, Pitié-Salpêtrière Hospital, INSERM UMRS_1138, Centre de Recherche des Cordeliers, Institute of Cardiometabolism and Nut…
  • Hôpital Haut-Lévêque, Department of Endocrinology, Diabetes and Nutrition, University of Bordeaux, Faculty of Medicine, INSERM unit 1034, Biology of Cardiovascular Diseases, Bordeaux University Hospital, Bordeaux, Franc…
  • Centre d'Investigation Clinique CIC1402, Université de Poitiers, CHU de Poitiers, INSERM, Poitiers, France.
  • L'institut du Thorax, INSERM, CNRS, UNIV Nantes, Diabetology Department, CHU Nantes, Nantes, France.

ORCID-Profile: Olivier Bourron, Samy Hadjadj

Förderung

  • Groupement pour l'Etude des Maladies Métaboliques et Systémiques (GEMMS Poitiers, France)
  • Société Francophone du Diabète
  • Association Française des Diabétiques
  • French Ministry of Health

Zitieren

APA

Bourron, O., Mohammedi, K., De Keizer, J., Schneider, F., Hadjadj, S., & Saulnier, P. J. (2024). A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15656

Vancouver

Bourron O, Mohammedi K, De Keizer J, Schneider F, Hadjadj S, Saulnier PJ. A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15656

BibTeX
@article{Bourron2024,
  author = {Bourron, Olivier and Mohammedi, Kamel and De Keizer, Joe and Schneider, Fabrice and Hadjadj, Samy and Saulnier, Pierre-Jean},
  title = {A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15656}
}
Kostenlos starten →